Advertisement Sciele Pharma seeks approval for new Sular formulation - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sciele Pharma seeks approval for new Sular formulation

Sciele Pharma has submitted a supplemental new drug application to the FDA for a new formulation of Sular.

The new formulation utilizes SkyePharma’s patented Geomatrix technology, which has been developed to provide a lower dose of Sular for each of its current doses.

Sular is designed to control high blood pressure.